Abstract
Objectives: Nigericin, an antibiotic derived from Streptomyces hygroscopicus, has been proved to exhibit promising anti-cancer effects on a variety of cancers. Our previous study investigated the potential anti-cancer properties in pancreatic cancer (PC), and demonstrated that nigericin could inhibit the cell viabilities in concentration- and time-dependent manners via differentially expressed circular RNAs (circRNAs). However, the knowledge of nigericin associated with long non-coding RNA (lncRNA) and mRNA in pancreatic cancer (PC) has not been studied. This study is to elucidate the underlying mechanism from the perspective of lncRNA and mRNA.Methods: The continuously varying molecules (lncRNAs and mRNAs) were comprehensively screened by high-throughput RNA sequencing.Results: Our data showed that 76 lncRNAs and 172 mRNAs were common differentially expressed in the nigericin anti-cancer process. Subsequently, the bioinformatics analyses, including Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, coding and non-coding co-expression network, cis- and trans-regulation predictions and protein-protein interaction (PPI) network, were applied to annotate the potential regulatory mechanisms among these coding and non-coding RNAs during the nigericin anti-cancer process.Conclusions: These findings provided new insight into the molecular mechanism of nigericin toward cancer cells, and suggested a possible clinical application in PC.
Highlights
Ductal adenocarcinoma of the exocrine pancreas, commonly known as pancreatic cancer (PC), is a highly aggressive malignancy with few effective therapies
Afterwards, we found that salinomycin could target on cisplatin-resistant colorectal cancer cells by accumulating reactive oxygen species [11]
For trans-regulation prediction, we focused on the manner that long non-coding RNA (lncRNA) played their functions via transcription factors (TFs)
Summary
Ductal adenocarcinoma of the exocrine pancreas, commonly known as pancreatic cancer (PC), is a highly aggressive malignancy with few effective therapies. At the time of diagnosis, −20% of PC patients are considered eligible for surgery and of these, about a half undergoes successful resection [1]. A majority of patients with PC are diagnosed at advanced stages, at which patients can hardly receive surgical R0 resection [2] with a 5-years survival rate of 3% and a median survival of
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
